Akagera announces positive Phase I data of AKG-100 in tuberculosis

Phase 1positiveAKG-100Positive

AI Analysis

Summary

Akagera Medicines announced positive Phase 1 data from its SAD segment trial of AKG-100, an investigational long-acting IV therapeutic for tuberculosis and drug-resistant tuberculosis.

Clinical Trial Data

Phase

Phase 1

Outcome Details

Positive data from SAD segment of first-in-human Phase I trial

Importance:5/10

Sentiment:

0.75

Phase 1 datatuberculosisdrug resistant TBIV therapeuticfirst-in-human

Related Companies

$TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on July 21, 2026 8:36 AM

Read Original